Heart Failure from Cancer Therapy: Can we Prevent It?
Key result
In cancer patients receiving anthracycline-based chemotherapy, beta-blockers and ACE inhibitors/ARBs significantly prevented LVEF decrease compared to controls (mean difference 2.57% and 4.71%).
Why the study?
Chemotherapy-induced cardiotoxicity and left ventricular dysfunction impair prognosis, making prevention crucial.
Do beta-blockers or ACE inhibitors/ARBs prevent a decrease in LVEF in cancer patients receiving anthracycline-based chemotherapy?
Population
769 cancer patients in beta-blocker analysis and 581 in ACE inhibitors/ARBs analysis
Comparison
Beta-blockers or ACE inhibitors/ARBs vs controls
Design
Systematic review and meta-analysis of randomized controlled trials
Follow-up
6 months
Authors
Discussion
Loading...
Member takes
Implication
Beta-blockers and ACEi/ARBs modestly preserve LVEF during anthracycline therapy; extends RCT evidence for cardioprotection despite heterogeneity.
Key Points
- This meta-analysis explores the effectiveness of beta-blockers and ACE inhibitors/ARBs in preventing chemotherapy-induced cardiotoxicity in cancer patients.
- Systematic search of databases for randomized controlled trials published until February 2019.
- Included studies on left ventricular ejection fraction after 6 months of chemotherapy.
- Excluded studies on combination cardioprotective therapies.
- Beta-blocker group had an average LVEF improvement of 2.57% (95% CI 0.63-4.51, P=0.009) compared to controls.
- ACE inhibitors/ARBs showed a mean LVEF improvement of 4.71% (95% CI 0.38-9.03, P=0.03).
- Significant heterogeneity in beneficial effects across studies noted.
Study Design
Type
Meta-Analysis (n=1,350)
Structured PICO
Do beta-blockers or ACE inhibitors/ARBs prevent a decrease in LVEF in cancer patients receiving anthracycline-based chemotherapy?
P
Population
1,350 cancer patients receiving anthracycline-based chemotherapy across randomized trials assessing beta-blockers or ACE inhibitors/ARBs for prevention of cardiotoxicity.
I
Intervention
Beta-blockers or ACE inhibitors/ARBs for prevention of cardiotoxicity.
C
Comparator
Controls.
O
Outcome
Prevention of a decrease in left ventricular ejection fraction (LVEF) after 6 months of chemotherapy as defined by the individual study and assessed by either transthoracic echocardiography or magnetic resonance imaging.surrogate
Main Result
Mean Difference: 2.57 (95% CI 0.63–4.51)
p-value: p=0.009
Beta-blockers and ACE inhibitors/ARBs provide a moderate but significant benefit in preserving LVEF in cancer patients undergoing anthracycline-based chemotherapy.
Limitations
- Significant heterogeneity between the studies
Cite This Study
Totzeck et al. (2019) conducted a meta-analysis in Cancer (risk of cardiotoxicity from chemotherapy) (n=1,350). Beta-blockers or ACE inhibitors/ARBs vs. Controls was evaluated on Prevention of a decrease in LVEF (MD 2.57%, 95% CI 0.63-4.51, p=0.009). In cancer patients receiving anthracycline-based chemotherapy, beta-blockers and ACE inhibitors/ARBs significantly prevented LVEF decrease compared to controls (mean difference 2.57% and 4.71%).